Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Humana Inc. (NYSE: HUM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q as they are filed with the U.S. Securities and Exchange Commission. As a major participant in Medicare Advantage, Medicaid managed care and related health insurance lines, Humana uses these filings to report financial results, guidance, leadership changes and other material events.
Recent Form 8-K filings for Humana include Regulation FD disclosures reaffirming earnings guidance and providing reconciliations between GAAP earnings per common share and Adjusted earnings per common share (Adjusted EPS), which management uses to analyze core operating performance and inform planning and incentive compensation. Other 8-Ks describe results of operations for specific quarters, preliminary Medicare Advantage Star Ratings information, and leadership transitions in the insurance segment, such as the planned retirement of an Insurance Segment President and the appointment of new leaders for Medicare Advantage and the broader insurance business.
Filings also reflect Humana’s role as a health insurer and managed care organization. AM Best’s rating actions, while separate from SEC filings, complement the picture provided in regulatory reports by describing the financial strength and business profile of Humana’s health and dental insurance subsidiaries, collectively known as Humana Health Group, and by noting the contribution of the CenterWell segment as a non-insurance source of revenue and earnings.
On Stock Titan, investors and researchers can use AI-powered summaries to quickly interpret lengthy documents such as 10-K and 10-Q reports, focusing on topics that matter for a company like Humana: Medicare Advantage and Medicaid performance, Star Ratings dynamics, non-GAAP metrics like Adjusted EPS, capital structure, and risk disclosures. The filings page also surfaces insider and executive-related disclosures reported on Form 8-K, helping users track leadership changes and compensation-related arrangements referenced in those reports. Real-time updates from EDGAR combined with AI explanations make it easier to follow how Humana communicates its financial condition, strategic initiatives and regulatory developments over time.
Humana Inc. completed a public offering of $1.0 billion aggregate principal amount of 6.625% fixed-to-fixed rate junior subordinated notes due 2056. The notes were sold at 100% of principal under an effective shelf registration with several major banks as joint bookrunners.
The notes pay interest at 6.625% annually until September 15, 2031, then reset every five years to the Five-year U.S. Treasury Rate plus 2.891%, with a floor of 6.625%. Interest is payable each March 15 and September 15, and Humana may defer interest for up to 10 consecutive years if no event of default exists. The securities are unsecured and junior to Humana’s senior indebtedness, effectively junior to secured debt and subsidiary liabilities. Humana expects net proceeds of about $986 million, to be used for general corporate purposes, including potential repayment of existing debt and commercial paper.
Humana Inc. filed a definitive proxy statement to solicit votes for its 2026 Annual Meeting of Stockholders, to be held virtually on
Humana Inc. is offering $1,000,000,000 of 6.625% Fixed-to-Fixed Rate Junior Subordinated Notes due
Humana Inc. is asking stockholders to vote at its 2026 Annual Meeting, a virtual event on April 16, 2026 at 1:00 p.m. Eastern via www.virtualshareholdermeeting.com/HUM2026. Stockholders of record on February 27, 2026, when 120,054,462 shares were outstanding, may vote.
The board seeks approval of ten director nominees, ratification of PricewaterhouseCoopers as 2026 auditor, a non-binding say-on-pay vote, and a new 2026 Stock Incentive Plan, while recommending against a stockholder proposal. Humana highlights 2025 progress in Medicare Advantage, Medicaid and CenterWell, including improved care quality, higher member retention and Adjusted EPS above initial guidance.
Humana Inc. is offering a series of fixed-to-fixed rate junior subordinated notes due 2056. The notes carry an initial fixed rate to a
Humana Inc. filed Post-Effective Amendment No. 1 to its Form S-3 to add exhibits relating to its subordinated debt program.
The filing incorporates an Amended and Restated Indenture dated March 5, 2026 and a Statement of Eligibility on Form T-1 for The Bank of New York Mellon Trust Company, N.A. The amendment states that no changes were made to the base prospectus and that securities may be offered "from time to time after the effective date of this registration statement." The registration includes standard indemnification provisions and notes officers' and directors' insurance.
Humana Inc. filed an update stating that senior management will meet with investors and analysts between March 2 and March 31, 2026, and will reaffirm its full-year 2026 earnings guidance. The company continues to project at least
Humana also reiterates projected Adjusted (non-GAAP) EPS of at least
Humana Inc.'s Chief Legal Officer Joseph C. Ventura exercised stock options for 1,035 shares of Humana common stock on February 24, 2026, increasing his directly held stake to 17,565 shares. On the same day, 478 shares were disposed of at $177.075 per share to satisfy tax liabilities on performance stock units that vested on February 24, 2026, with no value received by him in return. Footnotes also note outstanding stock options granted under Humana’s 2019 Amended & Restated Stock Incentive Plan and that his direct holdings include 6,250 restricted stock units and performance stock units scheduled to vest on February 24, 2026.
Humana Inc. President, Insurance George Renaudin II reported option-related activity in Humana common stock. On 02/24/2026, he acquired 1,035 shares through an exercise of stock options and disposed of 419 shares at $177.075 per share to cover tax liabilities on performance stock vesting, receiving no cash value in return.